⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTXR News
Citius Pharmaceuticals Inc. Common
Centri Announces Participating Companies for Second Annual Capital Conference at Nasdaq
accessnewswire.com
ATYR
CTXR
MVBF
Form 8-K
sec.gov
CTXR
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
prnewswire.com
CTXR
CTOR
Form 8-K
sec.gov
CTXR
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
prnewswire.com
CTXR
CTOR
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
prnewswire.com
CTXR
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
prnewswire.com
CTXR
CTOR
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
prnewswire.com
CTXR
CTOR
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
prnewswire.com
CTXR
CTOR
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
prnewswire.com
CTXR
CTOR